Patent Litigations

1. Vtama patent expiration

VTAMA IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US11590088 April, 2024 Pending Dermavant Sciences GmbH et al. Encube Ethicals Pvt. Ltd.
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11590088 DERMAVANT SCI Use of Tapinarof for the treatment of chronic plaque psoriasis
Nov, 2039

(14 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 23, 2027

Drugs and Companies using TAPINAROF ingredient

NCE-1 date: 23 May, 2026

Market Authorisation Date: 23 May, 2022

Treatment: Topical treatment of plaque psoriasis in adults

Dosage: CREAM

More Information on Dosage

VTAMA family patents

Family Patents

2. Ozempic patent expiration

What is Ozempic?

Ozempic (semaglutide) is an injectable medication used to improve blood sugar levels in adults with type 2 diabetes. It belongs to a class of drugs called GLP-1 receptor agonists and works by mimicking the effects of the hormone GLP-1, which helps regulate blood sugar levels. Ozempic slows digestion and decreases appetite, leading to improved glycemic control and potential weight loss benefits.

What is the Ozempic controversy?

The injectable diabetes medication Ozempic (semaglutide) has recently seen its FDA-approved label updated to warn of potential serious intestinal side effects like obstruction or blockage. The newly added FDA warning highlights that Ozempic may cause severe gastrointestinal issues like intestinal obstruction, intense abdominal pain, vomiting, constipation, and abdominal swelling.

OZEMPIC's oppositions filed in EPO

OZEMPIC IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US10335462 March, 2024 Pending Novo Nordisk A/S Apotex Inc. et al.
US10335462 November, 2023 Trial Instituted Novo Nordisk A/S Sun Pharmaceutical Industries Ltd. et al.
US10335462 October, 2023 Trial Instituted Novo Nordisk A/S DR. REDDY'S LABORATORIES, INC. et al.
US10335462 March, 2023 Trial Instituted Novo Nordisk A/S Mylan Pharmaceuticals Inc. et al.
US8129343 March, 2023 Institution Denied Novo Nordisk A/S Mylan Pharmaceuticals Inc. et al.
US8536122 March, 2023 Institution Denied Novo Nordisk A/S Mylan Pharmaceuticals Inc. et al.
US8114833 March, 2022 Terminated-Settled Novo Nordisk A/S Fresenius Kabi USA, LLC
US8114833 December, 2019 Terminated-Settled Novo Nordisk A/S et al. Pfizer Inc. et al.
US8114833 July, 2020 Terminated-Settled Novo Nordisk A/S Pfizer Inc.
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8536122 NOVO Acylated GLP-1 compounds
Mar, 2026

(1 year, 1 month from now)

US8129343 NOVO Acylated GLP-1 compounds
Dec, 2031

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10335462 NOVO Use of long-acting GLP-1 peptides
Jun, 2033

(8 years from now)

US8114833 NOVO Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Aug, 2025

(6 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 05, 2022
New Indication(I-822) Jan 16, 2023
New Dosing Schedule(D-185) Mar 28, 2025

Drugs and Companies using SEMAGLUTIDE ingredient

NCE-1 date: 05 December, 2021

Market Authorisation Date: 05 December, 2017

Treatment: A method of treating type 2 diabetes comprising administering semaglutide once weekly in a amount of 1.0 mg to a subject in need thereof; An adjunct to diet and exercise to improve glycemic control in...

Dosage: SOLUTION

How can I launch a generic of OZEMPIC before it's drug patent expiration?
More Information on Dosage

OZEMPIC family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Lumify patent expiration

LUMIFY IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US11596600 February, 2024 Pending Eye Therapies, LLC et al. Dr. Reddy's Laboratories S.A. et al.
US11833245 January, 2024 Trial Instituted Eye Therapies, LLC et al. Dr. Reddy's Laboratories S.A. et al.
US8293742 November, 2021 Final Written Decision - Appealed Eye Therapies, LLC et al. Slayback Pharma LLC et al.
US9259425 November, 2021 Terminated-Settled Eye Therapies, LLC Slayback Pharma LLC
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9259425 BAUSCH AND LOMB INC Compositions and methods for eye whitening
Jul, 2030

(5 years from now)

US8293742 BAUSCH AND LOMB INC Preferential vasoconstriction compositions and methods of use
Jul, 2030

(5 years from now)

US11596600 BAUSCH AND LOMB INC Vasoconstriction compositions and methods of use
Jul, 2029

(4 years from now)

US11833245 BAUSCH AND LOMB INC Vasoconstriction compositions and methods of use
Jul, 2029

(4 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 22, 2020

Drugs and Companies using BRIMONIDINE TARTRATE ingredient

Market Authorisation Date: 22 December, 2017

Treatment: Relieves redness of the eye due to minor eye irritations

Dosage: SOLUTION/DROPS

How can I launch a generic of LUMIFY before it's drug patent expiration?
More Information on Dosage

LUMIFY family patents

Family Patents

4. Lumify Preservative Free patent expiration

LUMIFY PRESERVATIVE FREE IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US11596600 February, 2024 Pending Eye Therapies, LLC et al. Dr. Reddy's Laboratories S.A. et al.
US8293742 November, 2021 Final Written Decision - Appealed Eye Therapies, LLC et al. Slayback Pharma LLC et al.
US9259425 November, 2021 Terminated-Settled Eye Therapies, LLC Slayback Pharma LLC
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11596600 BAUSCH AND LOMB INC Vasoconstriction compositions and methods of use
Jul, 2029

(4 years from now)

US9259425 BAUSCH AND LOMB INC Compositions and methods for eye whitening
Jul, 2030

(5 years from now)

US8293742 BAUSCH AND LOMB INC Preferential vasoconstriction compositions and methods of use
Jul, 2030

(5 years from now)




Drugs and Companies using BRIMONIDINE TARTRATE ingredient

Market Authorisation Date: 19 April, 2024

Treatment: Relieves redness of the eye due to minor eye irritations

Dosage: SOLUTION/DROPS

More Information on Dosage

LUMIFY PRESERVATIVE FREE family patents

Family Patents

5. Elcys patent expiration

ELCYS IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US11642370 February, 2024 Institution Denied Exela Pharma Sciences, LLC Nexus Pharmaceuticals LLC
US10653719 September, 2020 Institution Denied Exela Pharma Sciences LLC Eton Pharmaceuticals, Inc.
US10583155 June, 2020 Terminated-Denied Exela Pharma Sciences, LLC Eton Pharmaceuticals Inc.
US10478453 May, 2020 Institution Denied Exela Pharma Sciences, LLC Eton Pharmaceuticals, Inc.
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10478453 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(13 years from now)

US10583155 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(13 years from now)

US10653719 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(13 years from now)

US11642370 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(13 years from now)




Drugs and Companies using CYSTEINE HYDROCHLORIDE ingredient

Market Authorisation Date: 16 April, 2019

Treatment: Method of using l-cysteine in an admixture for treating patients needing parenteral nutrition

Dosage: SOLUTION

How can I launch a generic of ELCYS before it's drug patent expiration?
More Information on Dosage

ELCYS family patents

Family Patents

6. Nouress patent expiration

NOURESS IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US11642370 February, 2024 Institution Denied Exela Pharma Sciences, LLC Nexus Pharmaceuticals LLC
US10653719 September, 2020 Institution Denied Exela Pharma Sciences LLC Eton Pharmaceuticals, Inc.
US10583155 June, 2020 Terminated-Denied Exela Pharma Sciences, LLC Eton Pharmaceuticals Inc.
US10478453 May, 2020 Institution Denied Exela Pharma Sciences, LLC Eton Pharmaceuticals, Inc.
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10583155 BAXTER HLTHCARE CORP Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(13 years from now)

US11642370 BAXTER HLTHCARE CORP Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(13 years from now)

US10653719 BAXTER HLTHCARE CORP Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(13 years from now)

US10478453 BAXTER HLTHCARE CORP Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(13 years from now)




Drugs and Companies using CYSTEINE HYDROCHLORIDE ingredient

Market Authorisation Date: 13 December, 2019

Treatment: Method of using l-cysteine in an admixture for treating patients needing parenteral nutrition

Dosage: SOLUTION

More Information on Dosage

NOURESS family patents

Family Patents

7. Imbruvica patent expiration

IMBRUVICA IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US11672803 November, 2023 Trial Instituted Pharmacyclics LLC BeiGene USA, Inc. et al.
US9795604 March, 2019 Final Written Decision Pharmacyclics LLC et al. Sandoz Inc. et al.
US8754090 April, 2015 Terminated-Denied Pharmacyclics, Inc. Coalition for Affordable Drugs IV LLC
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11672803 PHARMACYCLICS LLC Use of inhibitors of Brutons tyrosine kinase (Btk)
Jun, 2031

(6 years from now)

US8754090 PHARMACYCLICS LLC Use of inhibitors of bruton's tyrosine kinase (Btk)
Jun, 2031

(6 years from now)

US9795604 PHARMACYCLICS LLC Methods of treating and preventing graft versus host disease
Oct, 2034

(9 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-680) Feb 12, 2017
New Indication(I-689) Jul 28, 2017
New Indication(I-702) Jan 29, 2018
New Chemical Entity Exclusivity(NCE) Nov 13, 2018
New Indication(I-729) Mar 04, 2019
New Dosing Schedule(D-165) May 06, 2019
New Indication(I-736) May 06, 2019
New Indication(I-737) May 06, 2019
New Indication(I-741) Jan 18, 2020
New Indication(I-753) Aug 02, 2020
Orphan Drug Exclusivity(ODE-55) Nov 13, 2020
Orphan Drug Exclusivity(ODE-60) Feb 12, 2021
Orphan Drug Exclusivity(ODE-72) Jul 28, 2021
New Dosing Schedule(D-176) Aug 24, 2021
M(M-236) Jan 25, 2022
Orphan Drug Exclusivity(ODE-86) Jan 29, 2022
Orphan Drug Exclusivity(ODE-109) Mar 04, 2023
Orphan Drug Exclusivity(ODE-117) May 06, 2023
Orphan Drug Exclusivity(ODE-128) Jan 18, 2024
Orphan Drug Exclusivity(ODE) Aug 02, 2024
ODE*(ODE*) Aug 02, 2024
Orphan Drug Exclusivity(ODE-152) Aug 02, 2024
M(M-14) Aug 24, 2025
New Product(NP) Aug 24, 2025
New Patient Population(NPP) Aug 24, 2025
Pediatric Exclusivity(PED) Feb 24, 2026
Orphan Drug Exclusivity(ODE-405) Aug 24, 2029

Drugs and Companies using IBRUTINIB ingredient

NCE-1 date: 24 February, 2025

Market Authorisation Date: 20 December, 2017

Treatment: Treatment of chronic lymphocytic leukemia with 17p deletion; Treatment of mantle cell lymphoma; Treatment of adult patients with chronic graft-versus-host disease (cgvhd) after failure of one or more ...

Dosage: TABLET; CAPSULE; SUSPENSION

How can I launch a generic of IMBRUVICA before it's drug patent expiration?
More Information on Dosage

IMBRUVICA family patents

Family Patents

8. Arazlo patent expiration

ARAZLO IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US11311482 June, 2023 Institution Denied Bausch Health Ireland Limited et al. Padagis Israel Pharmaceuticals Ltd. et al.
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11311482 BAUSCH Topical compositions and methods for treating skin diseases
May, 2038

(13 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 18, 2022

Drugs and Companies using TAZAROTENE ingredient

Market Authorisation Date: 18 December, 2019

Treatment: Topical treatment of acne vulgaris in patients 9 years of age and older

Dosage: LOTION

How can I launch a generic of ARAZLO before it's drug patent expiration?
More Information on Dosage

ARAZLO family patents

Family Patents

9. Rybelsus patent expiration

RYBELSUS's oppositions filed in EPO

RYBELSUS IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US8129343 March, 2023 Institution Denied Novo Nordisk A/S Mylan Pharmaceuticals Inc. et al.
US8536122 March, 2023 Institution Denied Novo Nordisk A/S Mylan Pharmaceuticals Inc. et al.
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8536122 NOVO Acylated GLP-1 compounds
Mar, 2026

(1 year, 1 month from now)

US8129343 NOVO Acylated GLP-1 compounds
Dec, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 20, 2022
New Chemical Entity Exclusivity(NCE) Dec 05, 2022
M(M-252) Jan 16, 2023

Drugs and Companies using SEMAGLUTIDE ingredient

NCE-1 date: 05 December, 2021

Market Authorisation Date: 09 December, 2024

Treatment: Method of treating type 2 diabetes mellitus

Dosage: TABLET

More Information on Dosage

RYBELSUS family patents

Family Patents

10. Wegovy patent expiration

WEGOVY's oppositions filed in EPO

WEGOVY IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US8129343 March, 2023 Institution Denied Novo Nordisk A/S Mylan Pharmaceuticals Inc. et al.
US8536122 March, 2023 Institution Denied Novo Nordisk A/S Mylan Pharmaceuticals Inc. et al.
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8536122 NOVO Acylated GLP-1 compounds
Mar, 2026

(1 year, 1 month from now)

US8129343 NOVO Acylated GLP-1 compounds
Dec, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 05, 2022
New Product(NP) Jun 04, 2024
New Patient Population(NPP) Dec 23, 2025
New Dosing Schedule(D-190) Jul 21, 2026
New Indication(I-935) Mar 08, 2027

Drugs and Companies using SEMAGLUTIDE ingredient

NCE-1 date: 05 December, 2021

Market Authorisation Date: 04 June, 2021

Treatment: NA

Dosage: SOLUTION

How can I launch a generic of WEGOVY before it's drug patent expiration?
More Information on Dosage

WEGOVY family patents

Family Patents

11. Mavenclad patent expiration

MAVENCLAD's oppositions filed in EPO

MAVENCLAD IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US7713947 October, 2022 Trial Instituted Merck Serono SA TWi Pharmaceuticals, Inc.
US8377903 October, 2022 Trial Instituted Merck Serono SA TWi Pharmaceuticals, Inc.
US7713947 January, 2023 Trial Instituted Merck Serono SA Hopewell Pharma Ventures, Inc. et al.
US8377903 January, 2023 Trial Instituted Merck Serono SA Hopewell Pharma Ventures, Inc. et al.
US10849919 February, 2023 Terminated-Settled Ares Trading SA Hopewell Pharma Ventures, Inc. et al.
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8377903 EMD SERONO INC Cladribine regimen for treating multiple sclerosis
May, 2026

(1 year, 3 months from now)

US7713947 EMD SERONO INC Cladribine regimen for treating multiple sclerosis
Oct, 2026

(1 year, 8 months from now)

US10849919 EMD SERONO INC Cladribine regimen for treating progressive forms of multiple sclerosis
Nov, 2038

(13 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 29, 2022

Drugs and Companies using CLADRIBINE ingredient

Market Authorisation Date: 29 March, 2019

Treatment: Treating rrms or spms with oral cladribine: (i) 2-4 months induction with 1.7 mg/kg - 3.5 mg/kg cladribine; (ii) cladribine-free period of about 8-10 months; (iii) 2-4 months maintenance with about 1....

Dosage: TABLET

How can I launch a generic of MAVENCLAD before it's drug patent expiration?
More Information on Dosage

MAVENCLAD family patents

Family Patents

12. Onureg patent expiration

ONUREG's oppositions filed in EPO

ONUREG IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US8846628 February, 2023 Terminated-Settled CELGENE CORPORATION et al. Apotex Inc. et al.
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8846628 BRISTOL Oral formulations of cytidine analogs and methods of use thereof
Jun, 2030

(5 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 01, 2023
Orphan Drug Exclusivity(ODE-320) Sep 01, 2027

Drugs and Companies using AZACITIDINE ingredient

Market Authorisation Date: 01 September, 2020

Treatment: Continued treatment of adults with acute myeloid leukemia who achieved first complete remission (cr) or cr with incomplete blood count recovery following intensive induction chemotherapy and are not a...

Dosage: TABLET

How can I launch a generic of ONUREG before it's drug patent expiration?
More Information on Dosage

ONUREG family patents

Family Patents

13. Calquence patent expiration

CALQUENCE IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US10272083 February, 2023 Institution Denied Acerta Pharma B.V. et al. Sandoz Inc.
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10272083 ASTRAZENECA Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
Jan, 2035

(9 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 31, 2022
New Indication(I-817) Nov 21, 2022
Orphan Drug Exclusivity(ODE-175) Oct 31, 2024
Orphan Drug Exclusivity(ODE-274) Nov 21, 2026

Drugs and Companies using ACALABRUTINIB ingredient

NCE-1 date: 31 October, 2021

Market Authorisation Date: 31 October, 2017

Treatment: Treatment of adult patients with previously untreated small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab

Dosage: CAPSULE

How can I launch a generic of CALQUENCE before it's drug patent expiration?
More Information on Dosage

CALQUENCE family patents

Family Patents

14. Calquence patent expiration

CALQUENCE IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US10272083 February, 2023 Institution Denied Acerta Pharma B.V. et al. Sandoz Inc.
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10272083 ASTRAZENECA Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
Jan, 2035

(9 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 31, 2022
New Indication(I-817) Nov 21, 2022
Orphan Drug Exclusivity(ODE-175) Oct 31, 2024
Orphan Drug Exclusivity(ODE-274) Nov 21, 2026

Drugs and Companies using ACALABRUTINIB MALEATE ingredient

NCE-1 date: 31 October, 2021

Market Authorisation Date: 03 August, 2022

Treatment: Treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab by administering 100 mg of acalabrutinib twice daily

Dosage: TABLET

More Information on Dosage

CALQUENCE family patents

Family Patents

15. Venclexta patent expiration

VENCLEXTA IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US11110087 October, 2022 Final Written Decision - Appealed Genentech, Inc. et al. Dr. Reddy's Laboratories, Inc. et al.
US10993942 February, 2022 Final Written Decision - Appealed Genentech, Inc. et al. Dr. Reddy's Laboratories, Inc. et al.
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11110087 ABBVIE Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor
Sep, 2033

(8 years from now)

US10993942 ABBVIE Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor
Sep, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 11, 2021
New Indication(I-782) Jun 08, 2021
M(M-228) Jun 08, 2021
New Indication(I-789) Nov 21, 2021
New Indication(I-795) May 15, 2022
Orphan Drug Exclusivity(ODE) Apr 11, 2023
Orphan Drug Exclusivity(ODE-114) Apr 11, 2023
M(M-265) Oct 16, 2023
Orphan Drug Exclusivity(ODE-185) Jun 08, 2025
Orphan Drug Exclusivity(ODE-211) Nov 21, 2025
Orphan Drug Exclusivity(ODE-239) May 15, 2026

Drugs and Companies using VENETOCLAX ingredient

NCE-1 date: 11 April, 2020

Market Authorisation Date: 11 April, 2016

Treatment: Treatment of chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll) by orally administering venetoclax to an adult according to a dose ramp-up including a 100 mg per day dose; Treatmen...

Dosage: TABLET

How can I launch a generic of VENCLEXTA before it's drug patent expiration?
More Information on Dosage

VENCLEXTA family patents

Family Patents

16. Trulance patent expiration

TRULANCE's oppositions filed in EPO

TRULANCE IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US7041786 March, 2022 Final Written Decision - Appealed Bausch Health Ireland Limited et al. Mylan Pharmaceuticals Inc. et al.
US7041786 October, 2022 Final Written Decision - Appealed Bausch Health Ireland Limited et al. MSN Laboratories Private Ltd. et al.
US9610321 June, 2022 Institution Denied Bausch Health Ireland Limited et al. Mylan Pharmaceuticals Inc. et al.
US9616097 June, 2022 Institution Denied Bausch Health Ireland Limited et al. Mylan Pharmaceuticals Inc. et al.
US9919024 June, 2022 Institution Denied Bausch Health Ireland Limited et al. Mylan Pharmaceuticals Inc. et al.
US9925231 June, 2022 Institution Denied Bausch Health Ireland Limited et al. Mylan Pharmaceuticals Inc. et al.
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7041786 SALIX Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
Jan, 2028

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9919024 SALIX Formulations of guanylate cyclase C agonists and methods of use
Sep, 2031

(6 years from now)

US9610321 SALIX Formulations of guanylate cyclase C agonists and methods of use
Sep, 2031

(6 years from now)

US9925231 SALIX Formulations of guanylate cyclase C agonists and methods of use
Sep, 2031

(6 years from now)

US9616097 SALIX Formulations of guanylate cyclase C agonists and methods of use
Aug, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-764) Jan 24, 2021
New Chemical Entity Exclusivity(NCE) Jan 19, 2022

Drugs and Companies using PLECANATIDE ingredient

NCE-1 date: 19 January, 2021

Market Authorisation Date: 19 January, 2017

Treatment: Chronic idiopathic constipation; Irritable bowel syndrome with constipation

Dosage: TABLET

How can I launch a generic of TRULANCE before it's drug patent expiration?
More Information on Dosage

TRULANCE family patents

Family Patents

17. Xarelto patent expiration

XARELTO's oppositions filed in EPO

XARELTO IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US10828310 February, 2022 Final Written Decision - Appealed Bayer Pharma AG et al. Mylan Pharmaceuticals Inc. et al.
US10828310 September, 2022 Final Written Decision Bayer Pharma AG et al. InvaGen Pharmaceuticals, Inc. et al.
US10828310 September, 2022 Final Written Decision Bayer Pharma AG et al. Teva Pharmaceuticals USA, Inc
US9539218 May, 2018 Terminated-Denied Bayer Intellectual Property GmbH Mylan Pharmaceuticals Inc.
US7157456 October, 2016 Terminated Bayer Intellectual Property GmbH et al. Mylan Pharmaceuticals Inc et al.
US7585860 October, 2016 Terminated Bayer Intellectual Property GmbH et al. Mylan Pharmaceuticals Inc. et al.
US7592339 October, 2016 Terminated Bayer Intellectual Property GmbH et al. Mylan Pharmaceuticals Inc. et al.
US9539218 January, 2014 Decision Frank Misselwitz et al
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7585860 JANSSEN PHARMS Substituted oxazolidinones and their use in the field of blood coagulation
Dec, 2020

(4 years ago)

US7157456 JANSSEN PHARMS Substituted oxazolidinones and their use in the field of blood coagulation
Aug, 2024

(5 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7585860 JANSSEN PHARMS Substituted oxazolidinones and their use in the field of blood coagulation
Dec, 2020

(4 years ago)

US7592339 JANSSEN PHARMS Substituted oxazolidinones and their use in the field of blood coagulation
Dec, 2020

(4 years ago)

US10828310 JANSSEN PHARMS Reducing the risk of cardiovascular events
Jan, 2039

(13 years from now)

US9539218 JANSSEN PHARMS Prevention and treatment of thromboembolic disorders
Feb, 2034

(9 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-643) Nov 04, 2014
New Indication(I-660) Nov 02, 2015
New Indication(I-661) Nov 02, 2015
New Indication(I-662) Nov 02, 2015
New Chemical Entity Exclusivity(NCE) Jul 01, 2016
New Dosing Schedule(D-168) Oct 27, 2020
New Indication(I-824) Oct 11, 2021
New Indication(I-810) Oct 11, 2022
M(M-284) Mar 10, 2023
New Indication(I-867) Aug 23, 2024
New Product(NP) Dec 20, 2024
Pediatric Exclusivity(PED) Jun 20, 2025

Drugs and Companies using RIVAROXABAN ingredient

NCE-1 date: 24 February, 2024

Market Authorisation Date: 11 October, 2018

Treatment: Reduction in the risk of recurrence of deep vein thrombosis (dvt) and pulmonary embolism; Prophylaxis of deep vein thrombosis (dvt); Reduction of risk of myocardial infarction and ischemic stroke in p...

Dosage: TABLET; FOR SUSPENSION

How can I launch a generic of XARELTO before it's drug patent expiration?
More Information on Dosage

XARELTO family patents

Family Patents

18. Idhifa patent expiration

IDHIFA IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US10610125 August, 2022 Terminated-Settled Servier Pharmaceuticals LLC et al. Rigel Pharmaceuticals, Inc.
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10610125 BRISTOL MYERS SQUIBB Methods and compositions for cell-proliferation-related disorders
Jun, 2030

(5 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 01, 2022
Orphan Drug Exclusivity(ODE) Aug 01, 2024
Orphan Drug Exclusivity(ODE-151) Aug 01, 2024

Drugs and Companies using ENASIDENIB MESYLATE ingredient

NCE-1 date: 01 August, 2021

Market Authorisation Date: 01 August, 2017

Treatment: Treatment of relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation

Dosage: TABLET

More Information on Dosage

IDHIFA family patents

Family Patents

19. Tibsovo patent expiration

TIBSOVO IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US10610125 August, 2022 Terminated-Settled Servier Pharmaceuticals LLC et al. Rigel Pharmaceuticals, Inc.
Can you believe TIBSOVO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10610125 SERVIER Methods and compositions for cell-proliferation-related disorders
Jun, 2030

(5 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-816) May 02, 2022
New Chemical Entity Exclusivity(NCE) Jul 20, 2023
New Indication(I-875) Aug 25, 2024
New Indication(I-893) May 25, 2025
Orphan Drug Exclusivity(ODE-203) Jul 20, 2025
Orphan Drug Exclusivity(ODE-242) May 02, 2026
New Indication(I-924) Oct 24, 2026
Orphan Drug Exclusivity(ODE-368) Aug 25, 2028
Orphan Drug Exclusivity(ODE-447) Oct 24, 2030

Drugs and Companies using IVOSIDENIB ingredient

NCE-1 date: 20 July, 2022

Market Authorisation Date: 20 July, 2018

Treatment: A method for treating newly diagnosed aml with ivosidenib and azacitidine wherein the aml has an idh1 mutation capable of converting alpha-ketoglutarate to 2-hydroxyglutarate (2hg)

Dosage: TABLET

How can I launch a generic of TIBSOVO before it's drug patent expiration?
More Information on Dosage

TIBSOVO family patents

Family Patents

20. Saxenda patent expiration

SAXENDA's oppositions filed in EPO

SAXENDA IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US8114833 March, 2022 Terminated-Settled Novo Nordisk A/S Fresenius Kabi USA, LLC
US8114833 December, 2019 Terminated-Settled Novo Nordisk A/S et al. Pfizer Inc. et al.
US8114833 July, 2020 Terminated-Settled Novo Nordisk A/S Pfizer Inc.
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8114833 NOVO Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Aug, 2025

(6 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 25, 2015
New Product(NP) Jan 25, 2017
New Patient Population(NPP) Dec 04, 2023

Drugs and Companies using LIRAGLUTIDE ingredient

NCE-1 date: 25 January, 2014

Market Authorisation Date: 23 December, 2014

Treatment: NA

Dosage: SOLUTION

How can I launch a generic of SAXENDA before it's drug patent expiration?
More Information on Dosage

SAXENDA family patents

Family Patents

21. Victoza patent expiration

VICTOZA's oppositions filed in EPO

VICTOZA IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US8114833 March, 2022 Terminated-Settled Novo Nordisk A/S Fresenius Kabi USA, LLC
US8114833 December, 2019 Terminated-Settled Novo Nordisk A/S et al. Pfizer Inc. et al.
US8114833 July, 2020 Terminated-Settled Novo Nordisk A/S Pfizer Inc.
US9265893 January, 2014 Decision Torben Stroem Hansen et al
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8114833 NOVO NORDISK INC Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Aug, 2025

(6 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265893 NOVO NORDISK INC Injection button
Sep, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 25, 2015
M(M-115) Apr 06, 2015
M(M-176) Apr 22, 2019
New Indication(I-750) Aug 25, 2020
New Patient Population(NPP) Jun 17, 2022
Pediatric Exclusivity(PED) Dec 17, 2022

Drugs and Companies using LIRAGLUTIDE ingredient

NCE-1 date: 17 December, 2021

Market Authorisation Date: 25 January, 2010

Treatment: NA

Dosage: SOLUTION

How can I launch a generic of VICTOZA before it's drug patent expiration?
More Information on Dosage

VICTOZA family patents

Family Patents

22. Lupkynis patent expiration

LUPKYNIS IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US10286036 February, 2022 Terminated-Settled Aurinia Pharmaceuticals Inc. Sun Pharmaceutical Industries Ltd. et al.
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10286036 AURINIA Protocol for treatment of lupus nephritis
Dec, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 22, 2026

Drugs and Companies using VOCLOSPORIN ingredient

NCE-1 date: 22 January, 2025

Market Authorisation Date: 22 January, 2021

Treatment: Treatment of patients with active lupus nephritis

Dosage: CAPSULE

More Information on Dosage

LUPKYNIS family patents

Family Patents

23. Vascepa patent expiration

VASCEPA's oppositions filed in EPO

VASCEPA IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US8642077 November, 2021 Terminated-Settled Amarin Pharmaceuticals Ireland Limited Hikma Pharmaceuticals USA Inc. et al.
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8642077 AMARIN PHARMS Stable pharmaceutical composition and methods of using same
Apr, 2030

(5 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jul 26, 2015
New Chemical Entity Exclusivity(NCE) Jul 26, 2017
New Indication(I-819) Dec 13, 2022

Drugs and Companies using ICOSAPENT ETHYL ingredient

NCE-1 date: 26 July, 2016

Market Authorisation Date: 26 July, 2012

Treatment: Use of vascepa to reduce triglycerides in a mixed dyslipidemia adult patient with elevated triglyceride (tg) levels (>= 150 mg/dl) and on statin therapy

Dosage: CAPSULE

How can I launch a generic of VASCEPA before it's drug patent expiration?
More Information on Dosage

VASCEPA family patents

Family Patents

24. Pedmark patent expiration

PEDMARK IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US10596190 October, 2021 Final Written Decision Oregon Health & Science University et al. Hope Medical Enterprises, Inc.
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10596190 FENNEC PHARMS INC Method for reducing ototoxicity in pediatric patients receiving platinum-based chemotherapy
Jan, 2038

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 20, 2025
Orphan Drug Exclusivity(ODE-384) Sep 20, 2029

Drugs and Companies using SODIUM THIOSULFATE ingredient

Market Authorisation Date: 20 September, 2022

Treatment: A method of reducing ototoxicity in a human pediatric patient about 5 years of age or under with localized medulloblastoma comprising administering sodium thiosulfate about six hours after administrat...

Dosage: SOLUTION

How can I launch a generic of PEDMARK before it's drug patent expiration?
More Information on Dosage

PEDMARK family patents

Family Patents

25. Thiola Ec patent expiration

THIOLA EC IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US11458104 October, 2021 Decision Mission Pharmacal Company
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11458104 MISSION PHARMACAL Enteric coated tiopronin tablet
Nov, 2038

(13 years from now)




Drug Exclusivity Drug Exclusivity Expiration
ODE*(ODE*) Jun 28, 2026

Drugs and Companies using TIOPRONIN ingredient

Market Authorisation Date: 28 June, 2019

Treatment: A method of treating cystinuria by orally administering tiopronin with food to prevent cystine stone formation in adults and pediatric patients with severe homozygous cystinuria

Dosage: TABLET, DELAYED RELEASE

How can I launch a generic of THIOLA EC before it's drug patent expiration?
More Information on Dosage

THIOLA EC family patents

Family Patents

26. Levulan patent expiration

LEVULAN IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US10357567 October, 2021 Terminated DUSA Pharmaceuticals, Inc. et al. Biofrontera Inc. et al.
US8216289 August, 2018 Terminated-Denied DUSA Pharmaceuticals Inc. Biofrontera Incorporated
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8216289 SUN PHARM INDS INC Illuminator for photodynamic therapy
May, 2018

(6 years ago)

US10357567 SUN PHARM INDS INC Methods for photodynamic therapy
Jan, 2038

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-82) Mar 12, 2013
New Indication(I-766) Mar 09, 2021

Drugs and Companies using AMINOLEVULINIC ACID HYDROCHLORIDE ingredient

Market Authorisation Date: 03 December, 1999

Treatment: Treatment of non-hyperkeratotic actinic keratoses of face and scalp; Treatment of actinic keratoses of upper extremities by photodynamic therapy

Dosage: SOLUTION

More Information on Dosage

LEVULAN family patents

Family Patents

27. Austedo patent expiration

AUSTEDO IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US8524733 September, 2021 Terminated-Denied Auspex Pharmaceuticals, Inc. Apotex Inc.
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8524733 TEVA BRANDED PHARM Benzoquinoline inhibitors of vesicular monoamine transporter 2
Apr, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-751) Aug 30, 2020
New Chemical Entity Exclusivity(NCE) Apr 03, 2022
Orphan Drug Exclusivity(ODE) Apr 03, 2024
Orphan Drug Exclusivity(ODE-134) Apr 03, 2024
M(M-54) Jun 24, 2024
Pediatric Exclusivity(PED) Dec 24, 2024

Drugs and Companies using DEUTETRABENAZINE ingredient

NCE-1 date: 25 December, 2023

Market Authorisation Date: 03 April, 2017

Treatment: NA

Dosage: TABLET

How can I launch a generic of AUSTEDO before it's drug patent expiration?
More Information on Dosage

AUSTEDO family patents

Family Patents

28. Austedo Xr patent expiration

AUSTEDO XR IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US8524733 September, 2021 Terminated-Denied Auspex Pharmaceuticals, Inc. Apotex Inc.
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8524733 TEVA Benzoquinoline inhibitors of vesicular monoamine transporter 2
Apr, 2031

(6 years from now)




Drugs and Companies using DEUTETRABENAZINE ingredient

Market Authorisation Date: 17 February, 2023

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE

More Information on Dosage

AUSTEDO XR family patents

Family Patents

29. Chantix patent expiration

CHANTIX IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US6890927 June, 2021 Terminated-Settled Pfizer Inc. Apotex Inc. et al.
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6890927 PF PRISM CV Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
May, 2022

(2 years ago)




Drug Exclusivity Drug Exclusivity Expiration
M(M-105) Jul 22, 2014
M(M-143) Oct 15, 2017
M(M-144) Oct 15, 2017
M(M-183) Aug 12, 2019
M(M-192) Dec 16, 2019
M(M-237) Feb 22, 2022
Pediatric Exclusivity(PED) Aug 22, 2022

Drugs and Companies using VARENICLINE TARTRATE ingredient

Market Authorisation Date: 10 May, 2006

Treatment: Aid to smoking cessation

Dosage: TABLET

How can I launch a generic of CHANTIX before it's drug patent expiration?
More Information on Dosage

CHANTIX family patents

Family Patents

30. Qelbree patent expiration

QELBREE IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US11324753 February, 2021 Decision Supernus Pharmaceuticals, Inc.
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11324753 SUPERNUS PHARMS Method of treatment of attention deficit/hyperactivity disorder (ADHD)
Sep, 2029

(4 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Apr 29, 2025
New Chemical Entity Exclusivity(NCE) Apr 02, 2026

Drugs and Companies using VILOXAZINE HYDROCHLORIDE ingredient

NCE-1 date: 02 April, 2025

Market Authorisation Date: 02 April, 2021

Treatment: For the treatment of attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE

More Information on Dosage

QELBREE family patents

Family Patents

31. Tyvaso patent expiration

TYVASO IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US10716793 January, 2021 Final Written Decision - Appealed United Therapeutics Corporation Liquidia Technologies, Inc.
US9604901 March, 2020 FWD Entered United Therapeutics Corp. Liquidia Technolgies, Inc.
US9593066 March, 2020 Terminated-Denied United Therapeutics Corp. Liquidia Technologies, Inc.
US9339507 June, 2017 Terminated-Settled United Therapeutics Corp. Watson Laboratories, Inc.
US9358240 June, 2017 Terminated-Settled United Therapeutics Corp. Watson Laboratories, Inc.
US8497393 October, 2015 FWD Entered United Therapeutics Corporation SteadyMed Ltd.
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8497393 UNITED THERAP Process to prepare treprostinil, the active ingredient in RemodulinĀ®
Dec, 2028

(3 years from now)

US9593066 UNITED THERAP Process to prepare treprostinil, the active ingredient in remodulinĀ®
Dec, 2028

(3 years from now)

US9604901 UNITED THERAP Process to prepare treprostinil, the active ingredient in RemodulinĀ®
Dec, 2028

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9358240 UNITED THERAP Treprostinil administration by inhalation
May, 2028

(3 years from now)

US9339507 UNITED THERAP Treprostinil administration by inhalation
Mar, 2028

(3 years from now)

US10716793 UNITED THERAP Treprostinil administration by inhalation
May, 2027

(2 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Jul 30, 2012
Orphan Drug Exclusivity(ODE) Jul 30, 2016
M(M-145) May 20, 2017
New Indication(I-856) Mar 31, 2024

Drugs and Companies using TREPROSTINIL ingredient

Market Authorisation Date: 30 July, 2009

Treatment: Method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a device

Dosage: SOLUTION

How can I launch a generic of TYVASO before it's drug patent expiration?
More Information on Dosage

TYVASO family patents

Family Patents

32. Tyvaso Dpi patent expiration

TYVASO DPI IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US10716793 January, 2021 Final Written Decision - Appealed United Therapeutics Corporation Liquidia Technologies, Inc.
US9604901 March, 2020 FWD Entered United Therapeutics Corp. Liquidia Technolgies, Inc.
US9593066 March, 2020 Terminated-Denied United Therapeutics Corp. Liquidia Technologies, Inc.
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9593066 UNITED THERAP Process to prepare treprostinil, the active ingredient in remodulinĀ®
Dec, 2028

(3 years from now)

US9604901 UNITED THERAP Process to prepare treprostinil, the active ingredient in RemodulinĀ®
Dec, 2028

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10716793 UNITED THERAP Treprostinil administration by inhalation
May, 2027

(2 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 23, 2025

Drugs and Companies using TREPROSTINIL ingredient

Market Authorisation Date: 23 May, 2022

Treatment: Method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a device

Dosage: POWDER

More Information on Dosage

TYVASO DPI family patents

Family Patents

33. Cerdelga patent expiration

CERDELGA's oppositions filed in EPO

CERDELGA IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US11458119 November, 2020 Decision Hanlan Liu et al.
US10888547 April, 2019 Decision Genzyme Corporation
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11458119 GENZYME CORP Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
Nov, 2030

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10888547 GENZYME CORP Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
Jan, 2031

(5 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 19, 2019
Orphan Drug Exclusivity(ODE) Aug 19, 2021
Orphan Drug Exclusivity(ODE-73) Aug 19, 2021

Drugs and Companies using ELIGLUSTAT TARTRATE ingredient

NCE-1 date: 19 August, 2018

Market Authorisation Date: 19 August, 2014

Treatment: Long-term treatment of adults with gaucher disease type 1 who are cyp2d6 extensive or intermediate metabolizers with 84 mg twice per day of eliglustat (equivalent to 100 mg of eliglustat tartrate twic...

Dosage: CAPSULE

How can I launch a generic of CERDELGA before it's drug patent expiration?
More Information on Dosage

CERDELGA family patents

Family Patents

34. Cabenuva Kit patent expiration

CABENUVA KIT's oppositions filed in EPO

CABENUVA KIT IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US11389447 October, 2020 Decision JANSSEN SCIENCES IRELAND UC
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11389447 VIIV HLTHCARE Aqueous suspensions of TMC278
Jun, 2027

(2 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-184) Jan 31, 2025
New Patient Population(NPP) Mar 29, 2025
New Chemical Entity Exclusivity(NCE) Jan 21, 2026

Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient

NCE-1 date: 21 January, 2025

Market Authorisation Date: 21 January, 2021

Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg by monthly administration of rilpivirine suspension as part of combination therapy

Dosage: SUSPENSION, EXTENDED RELEASE

More Information on Dosage

CABENUVA KIT family patents

Family Patents

35. Lutathera patent expiration

LUTATHERA IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US10596276 October, 2020 Institution Denied Advanced Accelerator Applications SA Evergreen Theragnostics, Inc.
US10596278 October, 2020 Terminated-Denied Advanced Accelerator Applications SA Evergreen Theragnostics, Inc.
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10596278 AAA USA INC Stable, concentrated radionuclide complex solutions
Jul, 2038

(13 years from now)

US10596276 AAA USA INC Stable, concentrated radionuclide complex solutions
Jul, 2038

(13 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 26, 2023
Orphan Drug Exclusivity(ODE-166) Jan 26, 2025
New Patient Population(NPP) Apr 23, 2027
Orphan Drug Exclusivity(ODE-479) Apr 23, 2031
Pediatric Exclusivity(PED) Oct 23, 2031

Drugs and Companies using LUTETIUM LU 177 DOTATATE ingredient

NCE-1 date: 23 October, 2030

Market Authorisation Date: 26 January, 2018

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

LUTATHERA family patents

Family Patents

36. Entresto patent expiration

ENTRESTO's oppositions filed in EPO

ENTRESTO IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US8101659 August, 2020 Terminated-Denied Novartis Pharmaceuticals Corporation Biocon Pharma Limited
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101659 NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition
Jan, 2025

(25 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 07, 2020
New Patient Population(NPP) Oct 01, 2022
Pediatric Exclusivity(PED) Apr 01, 2023
M(M-82) Feb 16, 2024

Drugs and Companies using SACUBITRIL; VALSARTAN ingredient

NCE-1 date: 01 April, 2022

Market Authorisation Date: 07 July, 2015

Treatment: NA

Dosage: TABLET

How can I launch a generic of ENTRESTO before it's drug patent expiration?
More Information on Dosage

ENTRESTO family patents

Family Patents

37. Entresto Sprinkle patent expiration

ENTRESTO SPRINKLE's oppositions filed in EPO

ENTRESTO SPRINKLE IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US8101659 August, 2020 Terminated-Denied Novartis Pharmaceuticals Corporation Biocon Pharma Limited
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101659 NOVARTIS Methods of treatment and pharmaceutical composition
Jan, 2025

(25 days ago)




Drugs and Companies using SACUBITRIL; VALSARTAN ingredient

Market Authorisation Date: 12 April, 2024

Treatment: NA

Dosage: CAPSULE, PELLETS

More Information on Dosage

ENTRESTO SPRINKLE family patents

Family Patents

38. Naproxen Sodium patent expiration

NAPROXEN SODIUM's oppositions filed in EPO

NAPROXEN SODIUM IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US11090280 July, 2020 Decision PATHEON SOFTGELS INC
US9693978 January, 2018 Terminated-Denied Patheon Softgels Inc. Catalent Pharma Solutions, Inc.
US9693979 January, 2018 Terminated-Denied Patheon Softgels Inc. Catalent Pharma Solutions, Inc.
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9693979 BIONPHARMA Liquid dosage forms of sodium naproxen
Mar, 2026

(1 year, 21 days from now)

US9693978 BIONPHARMA Solvent system for enhancing the solubility of pharmaceutical agents
Mar, 2026

(1 year, 21 days from now)

US11090280 BIONPHARMA Liquid dosage forms of sodium naproxen
Mar, 2026

(1 year, 21 days from now)




Drugs and Companies using NAPROXEN SODIUM ingredient

Market Authorisation Date: 17 February, 2006

Treatment: Temporary reduction of fever

Dosage: CAPSULE

How can I launch a generic of NAPROXEN SODIUM before it's drug patent expiration?
More Information on Dosage

NAPROXEN SODIUM family patents

Family Patents

39. Janumet patent expiration

JANUMET's oppositions filed in EPO

JANUMET IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US7326708 June, 2020 Final Written Decision Merck Sharp & Dohme Corp. et al. Dr. Reddy's Laboratories, Inc. et al.
US7326708 June, 2020 Final Written Decision Merck Sharp & Dohme Corp. et al. Sun Pharmaceutical Industries Ltd. et al.
US7326708 October, 2019 Final Written Decision Merck Sharp & Dohme Corp. et al. Mylan Pharmaceuticals, Inc.
US7326708 June, 2020 Terminated-Settled Merck Sharp & Dohme Corp. Teva Pharmaceuticals USA, Inc.
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7326708 MSD SUB MERCK Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Nov, 2026

(1 year, 9 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 16, 2011
M(M-244) Aug 12, 2022
M(M-187) Dec 04, 2023
Pediatric Exclusivity(PED) Jun 04, 2024

Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient

NCE-1 date: 05 June, 2023

Market Authorisation Date: 30 March, 2007

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor

Dosage: TABLET

How can I launch a generic of JANUMET before it's drug patent expiration?
More Information on Dosage

JANUMET family patents

Family Patents

40. Janumet Xr patent expiration

JANUMET XR's oppositions filed in EPO

JANUMET XR IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US7326708 June, 2020 Final Written Decision Merck Sharp & Dohme Corp. et al. Dr. Reddy's Laboratories, Inc. et al.
US7326708 June, 2020 Final Written Decision Merck Sharp & Dohme Corp. et al. Sun Pharmaceutical Industries Ltd. et al.
US7326708 October, 2019 Final Written Decision Merck Sharp & Dohme Corp. et al. Mylan Pharmaceuticals, Inc.
US7326708 June, 2020 Terminated-Settled Merck Sharp & Dohme Corp. Teva Pharmaceuticals USA, Inc.
US6340475 April, 2014 Final Written Decision Depomed, Inc. Endo Pharmaceutical Inc. et al.
US6635280 April, 2014 Final Written Decision Depomed, Inc. Endo Pharmaceutical Inc. et al.
US6340475 January, 2014 FWD Entered Depomed, Inc. Purdue Pharma L.P.
US6635280 January, 2014 FWD Entered DepoMed, Inc. Purdue Pharma L.P.
US6340475 April, 2014 Institution Denied Depomed, Inc. Endo Pharmaceutical Inc. et al.
US6635280 April, 2014 Institution Denied Depomed, Inc. Endo Pharmaceutical Inc. et al.
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7326708 MSD SUB MERCK Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Nov, 2026

(1 year, 9 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6340475 MSD SUB MERCK Extending the duration of drug release within the stomach during the fed mode
Sep, 2016

(8 years ago)

US6635280 MSD SUB MERCK Extending the duration of drug release within the stomach during the fed mode
Sep, 2016

(8 years ago)




Drug Exclusivity Drug Exclusivity Expiration
M(M-244) Aug 12, 2022
Pediatric Exclusivity(PED) Jun 04, 2024
M(M-187) Dec 04, 2023

Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient

Market Authorisation Date: 02 February, 2012

Treatment: Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and metformin hcl extended release is appropriate

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of JANUMET XR before it's drug patent expiration?
More Information on Dosage

JANUMET XR family patents

Family Patents

41. Januvia patent expiration

JANUVIA's oppositions filed in EPO

JANUVIA IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US7326708 June, 2020 Final Written Decision Merck Sharp & Dohme Corp. et al. Dr. Reddy's Laboratories, Inc. et al.
US7326708 June, 2020 Final Written Decision Merck Sharp & Dohme Corp. et al. Sun Pharmaceutical Industries Ltd. et al.
US7326708 October, 2019 Final Written Decision Merck Sharp & Dohme Corp. et al. Mylan Pharmaceuticals, Inc.
US7326708 June, 2020 Terminated-Settled Merck Sharp & Dohme Corp. Teva Pharmaceuticals USA, Inc.
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7326708 MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Nov, 2026

(1 year, 9 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 16, 2011
M(M-244) Aug 12, 2022
M(M-187) Dec 04, 2023
Pediatric Exclusivity(PED) Jun 04, 2024

Drugs and Companies using SITAGLIPTIN PHOSPHATE ingredient

NCE-1 date: 05 June, 2023

Market Authorisation Date: 16 October, 2006

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor

Dosage: TABLET

How can I launch a generic of JANUVIA before it's drug patent expiration?
More Information on Dosage

JANUVIA family patents

Family Patents

42. Juvisync patent expiration

JUVISYNC's oppositions filed in EPO

JUVISYNC IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US7326708 June, 2020 Final Written Decision Merck Sharp & Dohme Corp. et al. Dr. Reddy's Laboratories, Inc. et al.
US7326708 June, 2020 Final Written Decision Merck Sharp & Dohme Corp. et al. Sun Pharmaceutical Industries Ltd. et al.
US7326708 October, 2019 Final Written Decision Merck Sharp & Dohme Corp. et al. Mylan Pharmaceuticals, Inc.
US7326708 June, 2020 Terminated-Settled Merck Sharp & Dohme Corp. Teva Pharmaceuticals USA, Inc.
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7326708 MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Apr, 2026

(1 year, 1 month from now)




Drugs and Companies using SIMVASTATIN; SITAGLIPTIN PHOSPHATE ingredient

Market Authorisation Date: 18 September, 2012

Treatment: Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and simvastatin is appropriate

Dosage: TABLET

More Information on Dosage

JUVISYNC family patents

Family Patents

43. Steglujan patent expiration

STEGLUJAN's oppositions filed in EPO

STEGLUJAN IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US7326708 June, 2020 Final Written Decision Merck Sharp & Dohme Corp. et al. Dr. Reddy's Laboratories, Inc. et al.
US7326708 June, 2020 Final Written Decision Merck Sharp & Dohme Corp. et al. Sun Pharmaceutical Industries Ltd. et al.
US7326708 October, 2019 Final Written Decision Merck Sharp & Dohme Corp. et al. Mylan Pharmaceuticals, Inc.
US7326708 June, 2020 Terminated-Settled Merck Sharp & Dohme Corp. Teva Pharmaceuticals USA, Inc.
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7326708 MSD SUB MERCK Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Nov, 2026

(1 year, 9 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 19, 2022
M(M-275) Sep 17, 2024

Drugs and Companies using ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE ingredient

NCE-1 date: 19 December, 2021

Market Authorisation Date: 19 December, 2017

Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Dosage: TABLET

More Information on Dosage

STEGLUJAN family patents

Family Patents

44. Latuda patent expiration

LATUDA IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US9815827 June, 2020 Final Written Decision Sumitomo Dainippon Pharma Co., Ltd. et al. Slayback Pharma LLC et al.
US9555027 April, 2017 Terminated-Settled Sumitomo Dainippon Pharma Co., Ltd. Par Pharmaceutical, Inc.
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9815827 SUNOVION PHARMS INC Agent for treatment of schizophrenia
Feb, 2024

(11 months ago)

US9555027 SUNOVION PHARMS INC Pharmaceutical composition
May, 2026

(1 year, 3 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-134) Apr 26, 2015
New Chemical Entity Exclusivity(NCE) Oct 28, 2015
New Indication(I-674) Jun 28, 2016
M(M-195) Jan 27, 2020
Pediatric Exclusivity(PED) Jul 27, 2020
New Patient Population(NPP) Mar 05, 2021

Drugs and Companies using LURASIDONE HYDROCHLORIDE ingredient

NCE-1 date: 28 July, 2019

Market Authorisation Date: 07 December, 2011

Treatment: Treatment of major depressive episodes associated with bipolar i disorder; Treatment of schizophrenia

Dosage: TABLET

How can I launch a generic of LATUDA before it's drug patent expiration?
More Information on Dosage

LATUDA family patents

Family Patents

45. Zynrelef Kit patent expiration

ZYNRELEF KIT IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US11083730 May, 2020 Decision Heron Therapeutics, Inc.
US11083797 May, 2020 Decision Heron Therapeutics, Inc.
US10898575 December, 2019 Decision Heron Therapeutics, Inc.
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10898575 HERON THERAPS INC Long-acting polymeric delivery systems
Apr, 2035

(10 years from now)

US11083797 HERON THERAPS INC Long-acting polymeric delivery systems
Apr, 2035

(10 years from now)

US11083730 HERON THERAPS INC Long-acting polymeric delivery systems
Apr, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 12, 2024
New Indication(I-933) Jan 23, 2027

Drugs and Companies using BUPIVACAINE; MELOXICAM ingredient

Market Authorisation Date: 12 May, 2021

Treatment: Treatment of postsurgical pain providing analgesia to a patient for up to 72 hours, for example, after bunionectomy, open inguinal herniorrhaphy, or total knee arthroplasty via soft tissue or periarti...

Dosage: SOLUTION, EXTENDED RELEASE

More Information on Dosage

ZYNRELEF KIT family patents

Family Patents

46. Orenitram patent expiration

ORENITRAM IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US9604901 March, 2020 FWD Entered United Therapeutics Corp. Liquidia Technolgies, Inc.
US9593066 March, 2020 Terminated-Denied United Therapeutics Corp. Liquidia Technologies, Inc.
US8497393 October, 2015 FWD Entered United Therapeutics Corporation SteadyMed Ltd.
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8497393 UNITED THERAP Process to prepare treprostinil, the active ingredient in RemodulinĀ®
Dec, 2028

(3 years from now)

US9593066 UNITED THERAP Process to prepare treprostinil, the active ingredient in remodulinĀ®
Dec, 2028

(3 years from now)

US9604901 UNITED THERAP Process to prepare treprostinil, the active ingredient in RemodulinĀ®
Dec, 2028

(3 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Dec 20, 2016
New Dosing Schedule(D-156) Jan 28, 2019
New Dosing Schedule(D-157) Jan 28, 2019
Orphan Drug Exclusivity(ODE-308) Dec 20, 2020
New Indication(I-820) Oct 18, 2022
Orphan Drug Exclusivity(ODE-272) Oct 18, 2026

Drugs and Companies using TREPROSTINIL DIOLAMINE ingredient

Market Authorisation Date: 20 December, 2013

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of ORENITRAM before it's drug patent expiration?
More Information on Dosage

ORENITRAM family patents

Family Patents

47. Remodulin patent expiration

REMODULIN IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US9604901 March, 2020 FWD Entered United Therapeutics Corp. Liquidia Technolgies, Inc.
US9593066 March, 2020 Terminated-Denied United Therapeutics Corp. Liquidia Technologies, Inc.
US8497393 October, 2015 FWD Entered United Therapeutics Corporation SteadyMed Ltd.
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8497393 UNITED THERAP Process to prepare treprostinil, the active ingredient in RemodulinĀ®
Dec, 2028

(3 years from now)

US9593066 UNITED THERAP Process to prepare treprostinil, the active ingredient in remodulinĀ®
Dec, 2028

(3 years from now)

US9604901 UNITED THERAP Process to prepare treprostinil, the active ingredient in RemodulinĀ®
Dec, 2028

(3 years from now)




Drugs and Companies using TREPROSTINIL ingredient

Market Authorisation Date: 28 September, 2023

Treatment: NA

Dosage: INJECTABLE; SOLUTION

How can I launch a generic of REMODULIN before it's drug patent expiration?
More Information on Dosage

REMODULIN family patents

Family Patents

48. Invega Sustenna patent expiration

INVEGA SUSTENNA's oppositions filed in EPO

INVEGA SUSTENNA IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US9439906 February, 2020 Terminated-Denied Janssen Pharmaceutica NV Mylan Laboratories Ltd.
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9439906 JANSSEN PHARMS Dosing regimen associated with long acting injectable paliperidone esters
Jan, 2031

(5 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 19, 2011
New Dosage Form(NDF) Jul 31, 2012
Pediatric Exclusivity(PED) Jan 31, 2013
M(M-119) Aug 29, 2015
New Indication(I-698) Nov 12, 2017
M(M-215) Dec 20, 2020

Drugs and Companies using PALIPERIDONE PALMITATE ingredient

NCE-1 date: 01 February, 2012

Market Authorisation Date: 31 July, 2009

Treatment: Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE

How can I launch a generic of INVEGA SUSTENNA before it's drug patent expiration?
More Information on Dosage

INVEGA SUSTENNA family patents

Family Patents

49. Dymista patent expiration

DYMISTA's oppositions filed in EPO

DYMISTA IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US8163723 January, 2020 Terminated-Denied Cipla Limited GlaxoSmithKline Consumer Healthcare Holdings (US) LLC
US8168620 January, 2020 Terminated-Denied Cipla Limited GlaxoSmithKline Consumer Healthcare Holdings (US) LLC
US9259428 January, 2020 Terminated-Denied Cipla Limited GlaxoSmithKline Consumer Healthcare Holdings (US) LLC
US9901585 January, 2020 Terminated-Denied Cipla Limited GlaxoSmithKline Consumer Healthcare Holdings (US) LLC
US8168620 February, 2017 Terminated-Settled Cipla Limited Argentum Pharmaceuticals LLC
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9259428 MYLAN SPECIALITY LP Combination of azelastine and fluticasone for nasal administration
Jun, 2023

(1 year, 7 months ago)

US8163723 MYLAN SPECIALITY LP Combination of azelastine and steroids
Aug, 2023

(1 year, 5 months ago)

US9901585 MYLAN SPECIALITY LP Combination of azelastine and fluticasone for nasal administration
Jun, 2023

(1 year, 7 months ago)

US8168620 MYLAN SPECIALITY LP Combination of azelastine and steroids
Feb, 2026

(1 year, 14 days from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) May 01, 2015
New Patient Population(NPP) Feb 20, 2018
Pediatric Exclusivity(PED) Aug 20, 2018

Drugs and Companies using AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 01 May, 2012

Treatment: Treatment of seasonal allergic rhinitis

Dosage: SPRAY, METERED

How can I launch a generic of DYMISTA before it's drug patent expiration?
More Information on Dosage

DYMISTA family patents

Family Patents

50. Pataday Once Daily Relief patent expiration

PATADAY ONCE DAILY RELIEF IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US9533053 December, 2019 Terminated-Denied Novartis AG AYLA PHARMA LLC
US8791154 June, 2018 Terminated-Settled Alcon Research Ltd. Cipla Limited
US9533053 June, 2018 Terminated-Settled Alcon Research Ltd. Cipla Limited
US8791154 February, 2016 Terminated-Settled Alcon Research, Ltd. Argentum Pharmaceuticals, LLC
US8791154 August, 2016 Terminated-Settled Alcon Research, Ltd. Apotex, Inc.
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8791154 ALCON LABS INC High concentration olopatadine ophthalmic composition
May, 2032

(7 years from now)

US9533053 ALCON LABS INC High concentration olopatadine ophthalmic composition
May, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 30, 2018
Pediatric Exclusivity(PED) Jul 30, 2018

Drugs and Companies using OLOPATADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 30 January, 2015

Treatment: Treatment of ocular itching associated with allergic conjunctivitis

Dosage: SOLUTION/DROPS

How can I launch a generic of PATADAY ONCE DAILY RELIEF before it's drug patent expiration?
More Information on Dosage

PATADAY ONCE DAILY RELIEF family patents

Family Patents

51. Cubicin patent expiration

CUBICIN's oppositions filed in EPO

CUBICIN IPR and PTAB Proceedings

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US9138456 November, 2019 Terminated-Denied Cubist Pharmaceuticals LLC Amneal Pharmaceuticals LLC
US8058238 July, 2015 Terminated-Settled Cubist Pharmaceuticals LLC Fresenius Kabi USA LLC
US8129342 July, 2015 Terminated-Settled Cubist Pharmaceuticals LLC Fresenius Kabi USA LLC
US6468967 November, 2014 FWD Entered Cubist Pharmaceuticals LLC Fresenius-Kabi USA LLC
US6852689 November, 2014 FWD Entered Cubist Pharmaceuticals LLC Fresenius-Kabi USA LLC
US8058238 July, 2015 Terminated-Denied Cubist Pharmaceuticals LLC Fresenius Kabi USA LLC
US6468967 October, 2014 Terminated-Denied Cubist Pharmaceuticals, Inc. Agila Specialties Inc.
US6852689 October, 2014 Terminated-Denied Cubist Pharmaceuticals Incorporated Agila Specialties Inc.
US8058238 October, 2014 Terminated-Denied Cubist Pharmaceuticals, Inc. Agila Specialities Inc.
US8058238 October, 2014 Terminated-Denied Cubist Pharmaceuticals, Inc. Agila Specialties Inc.
US8129342 October, 2014 Terminated-Denied Cubist Pharmaceuticals, Inc. Agila Specialities Inc.
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9138456 CUBIST PHARMS LLC Lipopeptide compositions and related methods
Nov, 2030

(5 years from now)

US6468967 CUBIST PHARMS LLC Methods for administration of antibiotics
Sep, 2019

(5 years ago)

US8058238 CUBIST PHARMS LLC High purity lipopeptides
Nov, 2020

(4 years ago)

US6852689 CUBIST PHARMS LLC Methods for administration of antibiotics
Sep, 2019

(5 years ago)

US8129342 CUBIST PHARMS LLC High purity lipopeptides
Nov, 2020

(4 years ago)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Mar 29, 2020
M(M-211) Sep 01, 2020

Drugs and Companies using DAPTOMYCIN ingredient

Market Authorisation Date: 12 September, 2003

Treatment: Method of treating bacterial infections

Dosage: POWDER

How can I launch a generic of CUBICIN before it's drug patent expiration?